CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...